NCT03585595 (IBIS) is a Phase 3 clinical trial of Blood pressure lowering strategy in Ischemic Stroke, sponsored by Tulane University.

Who is sponsoring NCT03585595?

NCT03585595 is sponsored by Tulane University.

What drugs are being tested in NCT03585595?

Interventions in NCT03585595: Blood pressure lowering strategy.

What condition does NCT03585595 study?

NCT03585595 studies Ischemic Stroke.

Is NCT03585595 still recruiting?

NCT03585595 is currently withdrawn. Last updated 16 February 2023.

Last reviewed 2023-02-16 · How we verify

NCT03585595: IBIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intensive Blood Pressure Intervention in Stroke (IBIS) Trial

Withdrawn Phase 3 Last updated 16 February 2023

What this trial tests

Phase 3 trial testing Blood pressure lowering strategy in Ischemic Stroke. Withdrawn.

Timeline

1 January 2018

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Tulane University
Phase	Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Start date	1 January 2018
Primary completion	31 December 2022
Estimated completion	31 December 2022

Drugs / interventions tested

Blood pressure lowering strategy

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →

Sponsor

Tulane University

Who can join

40 and older, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators propose to conduct a multicenter randomized controlled trial to test the effect of a systolic blood pressure target of less than 120 mmHg (intensive treatment) compared to a target of less than 140 mmHg (standard treatment) on the risk of total recurrent stroke (ischemic and hemorrhagic) among patients with a recent ischemic stroke. The study findings will help in the development of clinical guidelines for blood pressure management among patients with ischemic stroke and will have an important global impact on reducing stroke-related morbidity and mortality.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The global epidemiology of hypertension.
Mills KT, Stefanescu A, He J. · · 2020 · cited 2422× · PMID 32024986 · DOI 10.1038/s41581-019-0244-2

Verify or expand the search:

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other Tulane University trials

Trials by the same sponsor.

NCT04007276 — The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients · Phase 4 · not yet recruiting
NCT07062406 — Enhancing Diabetes Care by Treating Insomnia · NA · not yet recruiting
NCT06810739 — The Women's Screening and Self-Testing Program (PROMETA) Study · NA · not yet recruiting
NCT05197998 — Promoting ColorBRAVE Conversations in Families · NA · suspended
NCT06261840 — Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03585595 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tulane University
Last refreshed: 16 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03585595.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing